Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 1029-1038

  Zatelli, Maria Chiara ^a   Luchin, Andrea ^a   Tagliati, Federico ^a   Leoni, Stefania ^a   Piccin, Daniela ^a   Bondanelli, Marta ^a   Rossi, Roberta ^a   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; GLYCOPROTEIN; GLYCOPROTEIN P 170; MULTIDRUG RESISTANCE PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CLONE; CELL STRAIN MCF 7; CELL VIABILITY; CYTOTOXICITY; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; NITROBENZENES; P-GLYCOPROTEIN; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SULFONAMIDES;

EID: 39149115694     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0114     Document Type: Article

References (28)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I & Gottesman MM 1999 Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 39 361-398.
2. Arun B & Goss P 2004 The role of COX-2 inhibition in breast cancer treatment and prevention. Seminars in Oncology 31 22-29.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A et al. 2005 Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 352 1092-1102.
4. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol/3-kinase/Akt-mediated activation of estrogen receptor a: a new model for anti-estrogen receptor resistance. Journal of Biological Chemistry 276 9817-9824.
5. Chow LW, Toi M & Takebayashi Y 2003 Neoadjuvant celecoxib and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) for the treatment oflocally advanced breast cancer (LABC). Proceedings of the American Society of Clinical Oncology 22 787-788.
6. Dannenberg AJ & Howe LR 2003 The role of COX-2 in breast and cervical cancer. Progress in Experimental Tumor Research 37 90-106.
7. Gasparini G, Longo R, Sarmiento R & Morabito A 2003 COX-2 inhibitors (Coxibs): a new class of anticancer agents? Lancet Oncology 4 605-615.
8. Gasparini G, Longo R, Torino F & Morabito A 2005 Therapy of breast cancer with molecular targeting agents. Annals of Oncology 16 28-36.
9. Gottesman MM 2002 Mechanisms of cancer drug resistance. Annual Review of Medicine 53 615-627.
10. Khuder SA & Mutgi AB 2001 Breast cancer and NSAID use: a meta-analysis. British Journal of Cancer 84 1188-1192.
11. Levenson AS & Jordan CV 1997 MCF7: the first hormone-responsive breast cancer cell line. Cancer Research 57 3071-3078.
12. McFadden DW, Riggs DR, Jackson BJ & Cunningham C 2006 Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. International Journal of Oncology 29 1019-1023.
13. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW & Verburg KM 2005 Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine 352 1081-1091.
14. Patel VA, Dunn MJ & Sorokin A 2002 Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. Journal of Biological Chemistry 277 38915-38920.
15. Pon YL, Auersperg N & Wong AS 2005 Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. Journal of Biological Chemistry 280 15438-15448.
16. Roberti A, La Sala D & Cinti C 2006 Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. Journal of Celluar Physiology 207 571-581.
17. Saltz L 2006 Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping? Seminars in Oncology 33 S28-S32.
18. Sarkadi B, Price EM, Boucher RC, Germann UA & Scarborough GA 1992 Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. Journal of Biological Chemistry 267 4854-4858.
19. Simstein R, Burow M, Parker A, Weldon C & Beckman B 2003 Apoptosis, chemoresistance, and breast cancer: insights from the MCF7 cell model system. Experimental Biology and Medicine 228 995-1003.
20. Solomon S, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M et al. 2005 Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 352 1071-1080.
21. Soule HD, Vazquez J, Long A, Albert S & Brennan MA 1973 human cell line from a pleural effusion derived from a breast carcinoma. Journal of National Cancer Institute 51 1409-1416.
22. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD & degli Uberti EC 2006 Role of complex Cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147 3530-3538.
23. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm K, van der Pol MA, Broxterman HJ, van Hinsbergh VWM & Lowik CGWM 2007 Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kB-mediated increase of intracellular doxorubicin accumulation. European Journal of Cancer 43 433-442.
24. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I et al. 2004 Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Research 64 1403-1410.
25. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M & degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochemical and Biophysical Research Communications 297 828-834.
26. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD & degli Uberti EC 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. Journal of Clinical Endocrinology and Metabolism 88 2797-2802.
27. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M & degli Uberti EC 2005a Cyclooxigenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a P-gp mediated mechanism. Journal of Clinical Endocrinology and Metabolism 90 5754-5760.
28. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A & degli Uberti EC 20056 SHP-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 146 2692-2698.